(Q37998604)

26 August 2017

title

Changing Crohn's disease management: need for new goals and indices to prevent disability and improve quality of life (English)

1 reference

26 August 2017

0 references

0 references

1 reference

3

Paul Emery

0 references

Jean-Frédéric Colombel

series ordinal

2

object named as

Jean-Frédéric Colombel

1 reference

26 August 2017

William Jeffery Sandborn

series ordinal

5

object named as

William J Sandborn

1 reference

26 August 2017

Daniel Hommes

1

1 reference

26 August 2017

Marco Greco

series ordinal

4

1 reference

26 August 2017

publication date

1 February 2012

1 reference

Journal of Crohn's and Colitis

26 August 2017

published in

1 reference

26 August 2017

volume

6 Suppl 2

1 reference

26 August 2017

page(s)

S224-34

1 reference

Long-term evolution of disease behavior of Crohn's disease

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960502-9

Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960502-9

Disease activity courses in a regional cohort of Crohn's disease patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960502-9

Overall and cause-specific mortality in Crohn's disease: a meta-analysis of population-based studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960502-9

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960502-9

Unfavourable outcome for women in a study of health-related quality of life, social factors and work disability in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960502-9

Disability in inflammatory bowel diseases: developing ICF Core Sets for patients with inflammatory bowel diseases based on the International Classification of Functioning, Disability, and Health

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960502-9

Persons with chronic conditions. Their prevalence and costs

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960502-9

The costs of Crohn's disease in the United States and other Western countries: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960502-9

The direct and indirect cost burden of Crohn's disease and ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960502-9

The quality of health care delivered to adults in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960502-9

Modifying unwarranted variations in health care: shared decision making using patient decision aids

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960502-9

Patient Self-management of Chronic Disease in Primary Care

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960502-9

E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided 'Constant-care' approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960502-9

Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960502-9

Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960502-9

Crohn Disease: mural attenuation and thickness at contrast-enhanced CT Enterography--correlation with endoscopic and histologic findings of inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960502-9

Magnetic resonance for assessment of disease activity and severity in ileocolonic Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960502-9

What changes in inflammatory bowel disease management can be implemented today?

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960502-9

Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial)

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960502-9

Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960502-9

Evidence for treating rheumatoid arthritis to target: results of a systematic literature search

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960502-9

Development of the Crohn's disease digestive damage score, the Lémann score

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960502-9

Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960502-9

The relationship between joint damage and functional disability in rheumatoid arthritis: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960502-9

Early rheumatoid arthritis: time to aim for remission?

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960502-9

Treating rheumatoid arthritis to target: recommendations of an international task force

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960502-9

Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug–induced clinical remission: Evidence from an imaging study may explain structural progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960502-9

An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960502-9

Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twe

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960502-9

Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960502-9

Benefits 8 years after a remission induction regime with an infliximab and methotrexate combination in early rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960502-9

American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960502-9

Infliximab, azathioprine, or combination therapy for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960502-9

Maintenance of Remission Among Patients With Crohn's Disease on Antimetabolite Therapy After Infliximab Therapy Is Stopped

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960502-9

Impact of inflammatory bowel disease on quality of life: Results of the European Federation of Crohn's and Ulcerative Colitis Associations (EFCCA) patient survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960502-9

7 January 2021

The cost of hospitalization in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960502-9

7 January 2021

What is value in health care?

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960502-9

7 January 2021

Home care's challenge: move the information...not the patient

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960502-9

7 January 2021

Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960502-9

7 January 2021

Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960502-9

7 January 2021

The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960502-9

7 January 2021

Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960502-9

7 January 2021

10.1016/S1873-9946(12)60502-9

Identifiers

DOI

1 reference

Dimensions Publication ID

26 August 2017

1027129244

0 references

1 reference